Cubist Systematic Strategies LLC boosted its position in shares of Alkermes Plc (NASDAQ:ALKS) by 9,248.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,807 shares of the company’s stock after buying an additional 12,670 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Alkermes were worth $651,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently bought and sold shares of ALKS. Toronto Dominion Bank raised its holdings in Alkermes by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares during the last quarter. Quantbot Technologies LP bought a new stake in Alkermes during the 3rd quarter valued at $126,000. Dynamic Technology Lab Private Ltd bought a new stake in Alkermes during the 3rd quarter valued at $214,000. Trexquant Investment LP bought a new stake in Alkermes during the 3rd quarter valued at $218,000. Finally, Greenwood Capital Associates LLC raised its holdings in Alkermes by 1.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after buying an additional 41 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.
Alkermes Plc (NASDAQ ALKS) opened at $53.04 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. Alkermes Plc has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a market cap of $8,240.00, a price-to-earnings ratio of -47.78 and a beta of 2.14.
A number of research firms recently commented on ALKS. Credit Suisse Group lowered their price target on shares of Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Barclays set a $50.00 price target on shares of Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Citigroup set a $62.00 price target on shares of Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. ValuEngine upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Finally, Mizuho set a $81.00 price objective on shares of Alkermes and gave the stock a “buy” rating in a report on Saturday, October 21st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $63.55.
In related news, SVP James M. Frates sold 20,932 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total value of $995,944.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $50.64, for a total transaction of $75,960.00. The disclosure for this sale can be found here. Insiders sold a total of 115,613 shares of company stock valued at $6,112,689 over the last 90 days. Company insiders own 5.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/25/alkermes-plc-alks-position-raised-by-cubist-systematic-strategies-llc.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.